Precigen, Inc. (NASDAQ:PGEN - Get Free Report) Director Nancy Agee acquired 3,411 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was acquired at an average price of $7.23 per share, with a total value of $24,661.53. Following the completion of the transaction, the director directly owned 309,187 shares of the company's stock, valued at $2,235,422.01. This trade represents a 1.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Precigen Price Performance
PGEN stock opened at $7.28 on Wednesday. Precigen, Inc. has a 52-week low of $2.99 and a 52-week high of $7.55. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -7.00 and a beta of 1.02. The business has a fifty day moving average of $5.91 and a two-hundred day moving average of $4.69.
Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company's revenue for the quarter was up 6322.7% on a year-over-year basis. As a group, research analysts anticipate that Precigen, Inc. will post 0.25 earnings per share for the current year.
Institutional Investors Weigh In On Precigen
Several large investors have recently added to or reduced their stakes in the business. Xponance LLC raised its holdings in Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company's stock worth $170,000 after acquiring an additional 2,993 shares in the last quarter. Composition Wealth LLC grew its holdings in Precigen by 16.5% during the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company's stock worth $89,000 after acquiring an additional 3,000 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company's stock valued at $263,000 after purchasing an additional 3,137 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Precigen by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company's stock valued at $1,449,000 after purchasing an additional 3,250 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms have recently issued reports on PGEN. Citigroup reissued an "outperform" rating on shares of Precigen in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research report on Friday, July 17th. Wall Street Zen upgraded Precigen from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Zacks Research raised Precigen from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 5th. Finally, Citizens Jmp boosted their price objective on Precigen from $9.00 to $11.00 and gave the company a "market outperform" rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.50.
View Our Latest Analysis on Precigen
Precigen News Roundup
Here are the key news stories impacting Precigen this week:
- Positive Sentiment: Strong PAPZIMEOS sales and quarterly profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the previous quarter. The company said the performance marked a commercial inflection point and helped it achieve quarterly profitability, supporting the stock’s upward momentum. Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
- Positive Sentiment: Pipeline progress adds to the investment case: PRGN-2009 is advancing in HPV-driven cancers, while management highlighted the broader potential of its AdenoVerse therapeutic platform. The combination of commercial revenue and pipeline development is reinforcing expectations for further growth. Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
- Positive Sentiment: New 1-year high: PGEN reached a new 52-week high, signaling strong recent trading momentum as investors responded to the company’s improved operating performance. Precigen Reaches New 1-Year High
- Positive Sentiment: Director purchase: Director Nancy H. Agee bought 3,411 shares at an average price of $7.23, modestly increasing her ownership. The purchase may be viewed as a sign of confidence in Precigen’s outlook.
- Neutral Sentiment: COO share sales were tax-related: COO Rutul R. Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the sales were planned and administrative, they provide limited bearish information, although they reduce his holdings.
- Neutral Sentiment: Short-interest data is inconclusive: Reported short interest was zero, making the published change and short-interest ratio unreliable as indicators of investor positioning.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
